SUMMARY
This study sought to investigate whether reactive oxygen species (ROS)-generating reduced nicotinamide adenine dinucleotide phosphate oxidase 2 (Nox2) contributes to calcific aortic valve disease (CAVD) or whether celastrol, a natural Nox2 inhibitor, may provide potential therapeutic target for CAVD. CAVD is an active and cellular-driven fibrocalcific process characterized by differentiation of aortic valvular interstitial cells (AVICs) toward an osteogenic-like phenotype. ROS levels increase in calcified aortic valves, while the sources of ROS and their roles in the pathogenesis of CAVD are elusive. The roles of Nox2 and the effects of celastrol were studied using cultured porcine AVICs in vitro and a rabbit CAVD model in vivo. Nox2 proteins were significantly upregulated in human aortic valves with CAVD. In vitro, Nox2 was markedly induced upon stimulation of AVICs with osteogenic medium, along with the increases in ROS production and calcium nodule formation. Celastrol (1) . In CAVD, the leaflets become thickened, fibrosed, stiffened, and calcified, resulting in valve sclerosis and progressive aortic stenosis, in which hemodynamic obstruction leads to cardiac hypertrophy and eventually heart failure, if untreated, with significant morbidity and mortality (2) . To date, aortic valve (AV) replacement or implantation is the only viable clinical option with no long-life guarantee, and there are no effective drug interventions to delay or retard its progression (3) . There is, therefore, a major unmet clinical need to identify other therapies capable of treating this disease.
It has been widely accepted that CAVD is an active and cellular-driven fibrocalcific disease, rather than a passive degeneration and inexorable consequence of aging (4) . At the microstructural level, a hallmark of CAVD is extensive fibrotic collagen accumulation and the presence of calcium-rich nodules on the valve surface and within the annulus region. Although the fibrotic and calcific mechanisms underlining CAVD are not fully understood, an increasing evidence from in vivo and in vitro studies suggests that activation of aortic valvular interstitial cells (AVICs) and their transdifferentiation into osteoblastic-like cells appears to be a central step in the disease initiation and development (5) . This phenotypic switch of quiescent AVICs to osteogenic myofibroblasts is supported by gene-profiling findings of increased valvular expression of osteoblast-specific marker proteins, such as osteopontin (OPN), and transcription factor, runtrelated transcription factor 2 (Runx2), which is essential for osteoblastic differentiation (1) . A number of molecules and signaling pathways have been identified to be critical in the regulation of AVIC differentiation, including the Notch (6) and Wnt/b-catenin pathways (7) .
The pathogenesis of CAVD is complex while previous studies suggest that reactive oxygen species (ROS) may be implicated in the cellular and extracellular alternations during the process of CAVD.
Evidence of increased ROS generation and decreased antioxidants has been shown both in experimental animal models of CAVD and in calcified region of human stenotic valves (8) (9) (10) (11) . The findings that increases in ROS precede AV dysfunction in a mouse CAVD model suggest that oxidative stress may be causative, not merely the readout of valve calcification and dysfunction (8) . Moreover, exogenous ROS promotes calcification of AVICs by activating profibrotic and pro-osteogenic signaling such as Runx2 (11) , strongly indicating that oxidative stress may precede the transdifferentiation of AVICs to an osteoblastic phenotype. However, the sources of ROS and their roles in CAVD remain elusive.
Reduced nicotinamide adenine dinucleotide phosphate oxidase 2 (Nox2) is a member of the Nox family proteins, which are major ROS sources in cardiovascular system (12) . Nox enzymes produce ROS as their primary function and are therefore especially important in redox signaling. Nox2 is widely expressed in cardiac and vascular cells and is acutely activated by agonists, metabolic factors, or mechanical forces in a process that involves association with p47 phox , p67 phox , p40 phox , and Rac1 cytosolic subunits. A large number of studies indicate that Nox2 is a pivotal player in the pathogenesis of diverse cardiovascular diseases including cardiac hypertrophy, fibrosis and remodeling (13) , as well as inflammation, metabolic disorders, and atherosclerosis (14) . Interestingly, it was reported that Nox2 might be involved in vascular calcification (15, 16) . A few studies showed that the expression levels of Nox2 were altered in calcified aortic valves (9, 17) . It is unknown, however, whether Nox2 contributes to CAVD or whether its involvement may provide a potential therapeutic target in the development of CAVD.
Celastrol, a pentacyclic triterpene naturally extracted from the roots of the Chinese Thunder God wine Tripterygium wilflordii, has long been used for the treatment of cancer, neurodegeneration and autoimmune diseases (18) . Celastrol was recently identified as a leptin sensitizer and potential novel antiobesity drug (19, 20) . Celastrol also exhibits protection against inflammation (21) , fibrosis (22), metabolic disorders (23) , and atherosclerosis (24) , all being risk factors of CAVD and characterized by an increase in ROS production. Of note, celastrol may block ROS generation as a potent Nox inhibitor with higher potency against Nox2 (25) . However, whether celastrol has any beneficial effect on CAVD has not been investigated.
Here, we explore the hypothesis that Nox2 intrinsically contributes to the development of CAVD. Using cultured AVICs in vitro and a rabbit CAVD model in vivo, we found that celastrol inhibits Nox2mediated glycogen synthase kinase 3 beta (GSK3B)/ b-catenin pathway in AVICs, such that AV fibrocalcification and stenosis are alleviated and cardiac function is improved.
METHODS

Detailed methods are provided in the Supplemental
Appendix.
The control noncalcified AVs and tricuspid calcified AVs were explanted from patients undergoing valve replacement surgery.
Primary porcine AVICs were isolated and cultured.
To induce calcification, cells were incubated with osteogenic medium (OGM). AVICs were transfected with adenoviral vectors expressing a short hairpin sequence targeted against Nox2, human Nox2 (26), green fluorescent protein (GFP), or b-galactosidase (27) .
Animal experiments were conducted in accordance with institutional and national standards. Figure 1A) . By contrast, the diseased valves with CAVD exhibited intense Nox2 accumulation around the calcified region throughout the valves ( Figure 1A) . Quantification by Western blots showed that the levels of Nox2 were significantly upregulated around 2.6-fold in CAVD compared with noncalcification valves, accompanying with higher expression of calcific marker Runx2 ( Figure 1B) . Moreover, the protein levels of Nox2 were positively correlated with Runx2 proteins as a surrogate marker of the severity of AV calcification ( Figure 1C ). 
CELASTROL INHIBITS GSK3B/b-CATENIN SIGNALING IN
AVICs. Previous works showed that GSK3B and bcatenin pathways are crucial regulators in the development of fibrogenesis and osteogenesis of AVs (7, 29) . We found that stimulation of AVICs with OGM caused GSK3B inactivation via phosphorylation of serine 9 (S9) and resulted in b-catenin accumulation, is similar to human clinical condition (28, 30) . With safety concern regarding the clinical use of celastrol, we first examined if celastrol had any side effects in rabbits. There was no evidence of liver damage or renal dysfunction with oral administration of celastrol at the dosage of 1 mg/kg/day for 18 weeks by histology and plasma biochemical analysis (Supplemental Figures 4A and 4B ). In addition, we did not observe any cardiac toxic effect of celastrol at baseline in terms of normal heart weight-to-body weight ratio, heart rates and ejection fraction (Supplemental Figure 4C ). Figure 7F) , and bigger cardiomyocyte size by wheat germ agglutinin staining ( Figure 7G) . We documented the similar body weight among groups, while rabbits actually exhibited slight but not significant body weight loss after 18 weeks'
HCþvitD2 diet compared with chow diet control animals ( Figure 7E) .
Strikingly, administration of celastrol significantly mitigated the severity of aortic stenosis. Compared with HCþvitD2-fed rabbits, celastrol treatment substantially mitigated decrease in mean AV area by 12.7%, and the alleviation was still significant after Figure 8C) . We also observed markedly increased fibrotic marker fibronectin by immunohistochemistry ( Figures 8A and 8B) . The enhanced fibrosis was further confirmed by Masson's trichrome staining in HCþvitD2-treated rabbits ( Figures 8A and 8B) . Celastrol treatment markedly reduced HCþvitD2-induced calcium deposits ( Figures 8A and 8B) , OPN messenger RNA levels ( Figure 8C) , and fibronectin and fibrosis positive staining area ( Figures 8A and 8B Figure 7) , although it was reported that celastrol may protect against metabolic dysfunction and obesity in mice (19, 31) .
DISCUSSION
In this study, we found Nox2 levels increase in human Although it has been increasingly recognized that Nox2 could be an attractive candidate as a potential therapeutic target, specific and effective Nox2 inhibitors are not clinically available. Another issue to consider with respect to targeted Nox2 inhibition is the potential to compromise neutrophil function, but previous work showed that this requires very substantial Nox2 inhibition (38) , thus safe therapeutic targeting of cardiovascular Nox2 could be feasible.
Celastrol, a plant-derived constituent of traditional Chinese medicine, has been shown as a preferable
Nox2 inhibitor through interference with interaction between the tandem SH3 domain of p47 phox and the proline-rich region of p22 phox , which is essential for Nox2 activation (25) . Celastrol may also inhibit Nox1 via disrupting the binding of NOXO1 and p22 phox (25) , but Nox1 is undetectable in AVICs (data not shown).
We found that treatment of AVICs with celastrol markedly decreased ROS generation and significantly attenuated calcium nodule formation by 35%, the inhibitory effect similar to silencing endogenous Nox2. Next, we investigated whether celastrol could exert protection in vivo using an established rabbit CAVD model (28) . One concern regarding the clinical use of celastrol is its relatively narrow therapeutic window of dose together with the occurrence of some adverse side effects (39 CAVD is often termed a fibrocalcific disease because a hallmark of CAVD initiation is fibrotic collage accumulation that leads to sclerotic leaflets (49, 50) . Ectopic calcium deposits forming within these stiffened valves further decrease tissue compliance, eventually resulting in valve stenosis.
Pathological process involved in CAVD may act in parallel to promote valvular fibrosis and calcification.
We demonstrated that activation of Nox2-mdidated should not be discounted if a long-term and high dose of celastrol could be used for the treatment of patients with severe stenosis. Nanoparticle-coated and cell-targeted drug delivery will be a promising strategy to improve efficacy and safety of celastrol (55) .
CONCLUSIONS
In this study, we report that up-regulation of Nox2 is critically involved in AV calcification. Celastrol is effective to alleviate the osteoblastic differentiation of AVICs in vitro and mitigate AV fibrocalcification and stenosis in rabbits in vivo, likely through the inhibition of the Nox2-mediated GSK3B/b-catenin pathway in AVICs. The findings imply that targeted inhibition of Nox2 may be a possible therapeutic strategy in CAVD, and celastrol could potentially be clinically useful for early intervention to mitigate the development of CAVD or slow stenosis.
